HENGRUI PHARMA - Jiangsu Hengrui Pharmaceutical Co., Ltd.’s Proposal on Purchasing Liability Insurance for Directors and Senior Management
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Jiangsu Hengrui Pharmaceutical Co., Ltd.
(a joint stock limited company incorporated in the People's Republic of China)
(Stock code: 1276)
Overseas regulatory announcement
This announcement is made in accordance with Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.
In accordance with the relevant laws and regulations of the People's Republic of China, Jiangsu Hengrui Pharmaceutical Co., Ltd. (the "Company") published the following announcement on the website of the Shanghai Stock Exchange (www.sse.com.cn). They are listed below for reference only.
By order of the board of directors
Jiangsu Hengrui Pharmaceutical Co., Ltd.
Chairman
Mr. Sun Piaoyang
Shanghai, China
March 25, 2026
As at the date of this announcement, the members of the Board include (i) executive directors Mr. Sun Piaoyang, Mr. Dai Hongbin, Ms. Feng Ji, Mr. Zhang Lianshan, Mr. Jiang Ningjun and Mr. Sun Jieping; (ii) non-executive director Ms. Guo Congzhao; and (iii) independent non-executive directors Mr. Dong Jiahong, Mr. Zeng Qingsheng, Mr. Sun Jinyun and Mr. Zhou Jien.
Securities code: 600276 Securities abbreviation: Hengrui Pharmaceutical Announcement Number: Lin 2026-051
Jiangsu Hengrui Pharmaceutical Co., Ltd.
Proposal on Purchasing Liability Insurance for Directors and Senior Management
The company's board of directors and all directors guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its contents.
Jiangsu Hengrui Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") held the 24th meeting of the ninth board of directors on March 25, 2026, and reviewed the "Proposal on Purchasing Liability Insurance for Directors and Senior Management Personnel". In order to improve the company's risk management system and protect the rights and interests of the company's directors and senior managers, the company plans to purchase liability insurance for the company and all directors and senior managers in accordance with the "Code of Governance for Listed Companies" and other relevant regulations.
The specific plan for purchasing liability insurance for directors and senior managers is as follows:
1.Insured person: Jiangsu Hengrui Pharmaceutical Co., Ltd.
Insured party: the company and all directors, senior managers and other directly responsible persons
Limit of liability: no more than RMB 200 million
Premium expenditure: no more than RMB 2 million per year (specifically, the final quotation data of the insurance company shall prevail)
Insurance period: The specific start and end time is subject to the insurance contract, and the insurance can be renewed every year.
In order to improve the efficiency of decision-making, the company's board of directors intends to request the shareholders' meeting to authorize the company's operating management to handle matters related to the purchase of liability insurance for the company and all directors and senior managers within the above authority (including but not limited to identifying other directly responsible personnel; identifying insurance companies; determining insurance amounts, insurance premiums and other insurance terms; Selecting and engaging insurance brokers or other intermediaries; signing relevant legal documents and handling other matters related to insurance, etc.), and handling matters related to renewal or re-insurance at or before the expiration of the liability insurance contract in the future. Renewal or re-insurance does not require separate decisions within the scope of the above insurance plan. Announcement is hereby made.
Board of Directors of Jiangsu Hengrui Pharmaceutical Co., Ltd.
March 25, 2026